Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the Piper Jaffray 27th Annual Healthcare Investor Conference in New York City.

About the Presentation

• Tuesday, December 1, 2015, at 2:00 p.m. Eastern Time
• The live audio webcast of the presentation can be accessed from the Investor Relations section of the company’s website at www.aimmune.com.
• A replay will be available for 14 days following the presentation.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut allergy and other food allergies. Aimmune Therapeutics’ characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to obtain clinically meaningful desensitization to food allergens. Aimmune Therapeutics plans to initiate enrollment in a Phase 3 study of its lead product, AR101, a complex mixture of natural peanut proteins and pharmaceutical-grade ingredients for the treatment of peanut allergy, one of the most common food allergies, at the beginning of 2016. For more information, please see www.aimmune.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151116005351/en/